Phase II Trial of Nemtabrutinib with CAR T-cell Therapy in Relapsed/Refractory CLL/SLL
A phase II trial is investigating the efficacy of combining nemtabrutinib with lisocabtagene maraleucel in patients with relapsed/refractory CLL/SLL.
Therapeutic Area
Therapeutic area intelligence for SLL with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.